Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Total Liabilities (2016 - 2025)

Sunshine Biopharma's Total Liabilities history spans 14 years, with the latest figure at $7.0 million for Q4 2025.

  • For Q4 2025, Total Liabilities changed 0.27% year-over-year to $7.0 million; the TTM value through Dec 2025 reached $7.0 million, changed 0.27%, while the annual FY2025 figure was $7.0 million, 0.27% changed from the prior year.
  • Total Liabilities reached $7.0 million in Q4 2025 per SBFM's latest filing, down from $7.3 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $7.6 million in Q4 2022 to a low of $95234.0 in Q1 2022.
  • Average Total Liabilities over 5 years is $4.8 million, with a median of $5.7 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: crashed 96.76% in 2022, then soared 7840.3% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $2.0 million in 2021, then soared by 282.49% to $7.6 million in 2022, then dropped by 19.39% to $6.1 million in 2023, then rose by 14.99% to $7.1 million in 2024, then fell by 0.27% to $7.0 million in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Total Liabilities are $7.0 million (Q4 2025), $7.3 million (Q3 2025), and $6.3 million (Q2 2025).